{Reference Type}: Journal Article
{Title}: Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
{Author}: Rajkumar SV;Bergsagel PL;Kumar S;
{Journal}: Hematol Oncol Clin North Am
{Volume}: 38
{Issue}: 2
{Year}: 2024 Apr 28
{Factor}: 2.861
{DOI}: 10.1016/j.hoc.2023.12.001
{Abstract}: Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors, patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM. Patients with newly diagnosed high-risk SMM are candidates for early intervention with lenalidomide or lenalidomide plus dexamethasone for 2 years, or enrollment in clinical trials.